Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Voruciclib Plus Venetoclax Shows Early Activity, Tolerability in Relapsed/Refractory AML

March 29th 2024

Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.

Ponatinib Plus Chemo Records Several ‘Firsts’ in Ph+ ALL and Becomes New SOC

March 29th 2024

Elias Jabbour, MD, expands on the significance of ponatinib’s approval in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

March 28th 2024

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

Supportive Care and Medication Access in GvHD

March 27th 2024

Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.

Dr Koehne on Efforts to Overcome CAR T-Cell Resistance in Hematologic Malignancies

March 27th 2024

Guenther Koehne, MD, PhD, discusses research efforts to overcome resistance to CAR T-cell therapy in hematologic malignancies.

Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

March 27th 2024

Drs Rampal and Kuykendall highlight the benefits of pacritinib for patients with low platelet counts, as evidenced by the PERSIST-2 study, and momelotinib for patients with anemia, as shown in the MOMENTUM Phase 3 Study, focusing on their efficacy in spleen volume reduction and symptom relief in patients with myelofibrosis.

Future Directions in Combination Therapies for Myelofibrosis

March 27th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, reflect on the future of combination therapies in treating myelofibrosis, emphasizing the need to align study endpoints with treatment goals and highlighting the potential of various combinations based on promising preclinical and early phase study results.

FDA Grants Priority Review to Revumenib for R/R KMT2A+ AML/ALL

March 26th 2024

The FDA granted priority review to the NDA seeking the approval of revumenib for the treatment of relapsed/refractory, KMT2A-rearranged acute leukemia.

Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

March 26th 2024

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.

Recent Data on Axi-Cel in Lymphoma

March 26th 2024

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

SLS009 Generates Positive Topline Data in R/R AML and REGAL Trial Completes Enrollment

March 26th 2024

Positive phase 2a topline findings have been announced with SLS009 plus azacitidine and venetoclax in relapsed/refractory acute myeloid leukemia.

Closing Thoughts on the MDS Treatment Landscape

March 26th 2024

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

Liposomal Annamycin Plus Cytarabine Generates Responses in AML

March 25th 2024

Liposomal annamycin plus cytarabine elicited responses in patients with acute myeloid leukemia, according to interim data from the phase 1b/2 MB-106 trial.

Dr Jabbour on the Significance of the FDA Approval of Ponatinib Plus Chemo for PH+ ALL

March 20th 2024

Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.

Therapies in Development for Chronic GvHD

March 20th 2024

Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.

Approved Therapies for Steroid-Refractory Chronic GvHD

March 20th 2024

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

March 20th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss luspatercept with or without ruxolitinib for the treatment of anemia in patients with myelofibrosis. The combination has demonstrated promise in reducing transfusion dependency, as seen in data from ACE-536-MF-001, with ongoing phase 3 trials.

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

March 20th 2024

Andrew Kuykendall, MD, highlights the potential of selinexor plus ruxolitinib in JAK inhibitor-naïve patients with MF based on promising response rates in XPORT-MF-034 updated results, with plans for a phase 3 study. He also noted the need to manage nausea as a adverse effect.

Subcutaneous Mosunetuzumab in Follicular Lymphoma

March 19th 2024

A hematologist-oncologist discusses a recent abstract looking at subcutaneous mosunetuzumab in the first line for patients with follicular lymphoma.

The Evolving Lymphoma Treatment Landscape

March 19th 2024

Lori A. Leslie, MD, a specialist in lymphoma, provides an overview of recent changes in the overall treatment landscape.